A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective

There have been 2040 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 34.9 %. There is no specific therapy. The current therapies have mainly been adapted from severe acute respiratory syndrome (SARS-CoV) treatments, incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabaan, Ali A., Alahmed, Shamsah H., Bazzi, Ali M., Alhani, Hatem M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Microbiology Society 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079582/
https://www.ncbi.nlm.nih.gov/pubmed/28855003
http://dx.doi.org/10.1099/jmm.0.000565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079582/
https://www.ncbi.nlm.nih.gov/pubmed/28855003
http://dx.doi.org/10.1099/jmm.0.000565

Ejemplares similares